http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108295242-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2016-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108295242-B |
| titleOfInvention | Pharmaceutical composition for preventing and/or treating psoriasis and application of CD317 extracellular domain protein |
| abstract | The invention provides a pharmaceutical composition for preventing and/or treating psoriasis and application of CD317 extracellular domain protein in preparing a medicament for preventing and/or treating psoriasis. Most of the existing treatment strategies for psoriasis are broad-spectrum inhibitors of TLR7/9 or IFN-alpha neutralizing antibodies, and the theory and practice prove that the methods can play a role in treating autoimmune psoriasis. However, these therapeutic means have a wide range of action and have a large inhibitory effect on the normal immune function of the body, so that the use range of these drugs is limited and these drugs can only be used for controlling acute allergic reactions in a short period of time. The CD317 extracellular domain protein takes ILT-7 specifically expressed on a human pDC cell as a target spot, and inhibits the generation of IFN-alpha through the target spot, thereby blocking the development of psoriasis at an early stage. Good specificity and far less influence on the normal immune function of the body than that of a broad-spectrum TLR7/9 inhibitor or IFN-alpha neutralizing antibody. |
| priorityDate | 2016-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.